Clinical Trials Logo
  1. Home
  2. Head and Neck Neoplasms
  3. NCT00328458
  4. Details
NCT00328458 Clinical Trial

EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients

Head and Neck Neoplasms Clinical Trial

Official title:
A Phase I, Open-label, Dose-escalation, Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00328458
Other study ID # 03C.275
Secondary ID 2003-33
Status Completed
Phase Phase 1
First received
Last updated
Start date February 2004
Est. completion date July 2009

Study information
Verified date July 2018
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.

Description:

- To determine the maximum tolerated dose (MTD) of EPO906 administered in combination with radiation therapy and establish a recommend phase II dose.

- To evaluate the safety and toxicity profile of EPO906 when administered concurrently with radiotherapy in three disease cohorts.

- To evaluate tumor response.

Recruitment information / eligibility
Status Completed
Enrollment 39
Est. completion date July 2009
Est. primary completion date May 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Requires a minimum of 3 weeks of radiation therapy

- Solid tumors with advanced or recurrent disease for which there is no standard therapy or tumors have failed standard therapy

- World Health Organization (WHO) performance status equal to or less than 2

- Life expectancy equal to or greater than 3 months

Exclusion Criteria:

- Any peripheral neuropathy

- Unresolved diarrhea greater than grade 1

- Patients who received any other investigational compound within the past 28 days

- Severe cardiac insufficiency

- Patients on Coumadin

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• EPO906 (epothilone B)

Locations
Country Name City State
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania

Sponsors (2)
Lead Sponsor Collaborator
Sidney Kimmel Cancer Center at Thomas Jefferson University Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) of EPO906 Baseline to 7 weeks
Secondary Number of participants that successful complete 7 weekly cycles of EPO906 concurrently with radiotherapy Baseline to 7 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05980598 - TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT02548377 - Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial N/A
Active, not recruiting NCT02229656 - Olaparib and Radiotherapy in Head and Neck Cancer Phase 1
Not yet recruiting NCT06289049 - Heavy Strength Training in Head and Neck Cancer Survivors Phase 2
Not yet recruiting NCT06347185 - Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study N/A
Terminated NCT02975739 - Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors N/A
Recruiting NCT00982436 - Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer Phase 1/Phase 2
Completed NCT01025518 - DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients N/A
Active, not recruiting NCT00248235 - Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer Phase 2/Phase 3
Completed NCT00135161 - Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer Phase 1
Terminated NCT00073450 - Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) Phase 2
Not yet recruiting NCT06458517 - Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers N/A
Completed NCT05269342 - Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer N/A
Recruiting NCT05544136 - A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer Phase 2
Terminated NCT03286972 - PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
Recruiting NCT04435938 - A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck Phase 2
Recruiting NCT03975465 - EMST and Swallowing in Long-Term Survivors of HNCA N/A
Recruiting NCT03678649 - A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC Phase 2
Completed NCT06446570 - Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma Phase 2
Completed NCT03292250 - Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] Phase 2

External Links